Business Wire

Life Edit Therapeutics to Present Data Demonstrating Therapeutic Potential of its Novel Gene Editing Platform

WALTHAM, Mass. & DURHAM, N.C.--(BUSINESS WIRE)--Life Edit ® Therapeutics Inc., an ElevateBio ® company focused on next-generation gene editing technologies and therapeutics, today announced the ...
Nasdaq

Editas (EDIT) Posts Upbeat Initial Data From SCD & TDT Studies

Editas Medicine EDIT announced positive preliminary safety and efficacy data from the first four patients with sickle cell disease (SCD) treated with EDIT-301 in the RUBY study and the first ...
Nasdaq

Initial Clinical Data from Editas Medicine’s BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the International Symposium on Retinal Degeneration in September

Company to host webcast investor event following the presentation on September 29 at 11:00 a.m. ET About EDIT-101 EDIT-101 is a CRISPR-based experimental medicine under investigation for the treatment ...
Seeking Alpha

Editas Medicine Reports In Vivo Proof-of-Concept Data for EDIT-401 at the European Society of Gene and Cell Therapy (ESGCT) 32nd Annual Congress

Robust efficacy data: ≥90% LDL-C reduction in non-human primates achieved within 48 hours of a single dose of EDIT-401; ≥90% LDL-C reduction in mice with high baseline LDL-C and reduced LDLR function ...
The Motley Fool

Where Will Editas Medicine Be in 1 Year?

Editas Medicine has some promising candidates, but plenty of work remains. The biotech's prospects look somewhat uncertain, making the stock risky. Within 12 months, a company can score meaningful ...